> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Vir Biotechnology's Hepatitis Delta Combination Meets Trial Goal With 44% Response
- URL: https://www.bullished.co/vir-biotechnologys-hepatitis-delta-combination-meets-trial-goal-with-44-response-3d966330/
- Published: 2026-11-12T09:26:11.000Z
- Updated: 2026-11-12T09:26:11.000Z
- Description: Selected patients kept viral suppression after stopping treatment, but Vir cautioned that the preliminary findings do not establish a cure.
- Author: Matteo Parrino
- Tags: SEC Filings, VIR, Industry: Healthcare

[Vir Biotechnology](https://www.bullished.co/tag/vir/), which develops experimental medicines for infectious diseases and cancer, met its main late-stage hepatitis delta trial goal with a [44% response](https://www.sec.gov/Archives/edgar/data/0001706431/000162828026071908/vir-20261108.htm?ref=bullished.co), versus 0% in the delayed-treatment group. Results presented Sunday and detailed in Monday's SEC filing also included preliminary viral-control findings after selected patients stopped treatment, which Vir cautioned do not establish a cure.

## Viral Control And Liver Measures

The combination pairs elebsiran, an experimental small interfering RNA medicine, with tobevibart, an experimental antibody, in monthly injections. The ongoing late-stage study enrolled 124 adults across multiple countries, including people with advanced disease: 83 received the combination and 41 were assigned to begin treatment at week 12.

The main goal combined undetectable hepatitis delta virus with normalization of ALT, a liver enzyme. The comparison measured treated patients at week 48 against the delayed-treatment group at week 12\. Both the main result and the key secondary result met the trial's statistical thresholds, with p-values below 0.0001.

Undetectable virus alone reached 79% in the combination group, versus 0% in the delayed-treatment group. Among treated patients, that rate was 85% for the 46 with cirrhosis and 73% for the 37 without it.

All combination-treated patients achieved either undetectable virus or the specified reduction in viral levels, versus 0% of the comparison group. ALT normalized in 53% versus 5%; an exploratory hepatitis B surface-antigen measure below 10 IU/mL was reached by 95% versus 0%.

One severe treatment-related event involved a fall in neutrophils, a type of white blood cell, that resolved within 15 days. Treatment continued without pauses or discontinuations. Most related side effects were temporary and mild or moderate; flu-like symptoms were most common, mainly after the first dose, and usually resolved within 24 to 48 hours.

## Off Treatment, With Follow-Up Still Running

In the ongoing mid-stage study, all 28 patients who completed 96 weeks of combination treatment had undetectable virus. Liver stiffness, a noninvasive measure associated with inflammation and scarring, [improved or stayed stable](https://www.sec.gov/Archives/edgar/data/0001706431/000162828026071908/vir-20261108.htm?ref=bullished.co) in 89%, or 24 of 27 patients with paired measurements. Side effects were mild or moderate, with no serious events or discontinuations linked to study drugs.

Patients who maintained undetectable virus for at least 96 weeks could choose to stop treatment. Ten did so, including seven with cirrhosis. All retained viral suppression through 12 weeks after their last dose; seven reached 24 weeks and one reached 48 weeks.

ALT levels stayed stable in all 10, with no observed viral rebound or liver-enzyme flares. Follow-up continues, however, and Vir said the exploratory findings involve selected patients, incomplete follow-up and a safety assessment still in progress. The results may change and cannot establish a lasting treatment-free response or cure.

## A Hepatitis Program In A Cancer Pivot

Vir began with infectious diseases and brought the COVID-19 antibody Xevudy to market in 2021\. It has since [restructured toward cancer](https://www.biopharmadive.com/news/vir-chronic-hepatitis-d-drug-results-elebsiran-tobevibart/874089/?ref=bullished.co) treatments that enlist immune-system T cells, while retaining hepatitis delta development. Its current medicines remain experimental candidates, not products approved for sale.

Norgine Pharma, Vir's commercialization partner for Europe, Australia and New Zealand, [licensed those rights](https://www.biospace.com/drug-development/virs-hepatitis-delta-combo-tamps-down-virus-as-gilead-showdown-looms?ref=bullished.co) in December 2025\. Vir secured €55 million upfront, with potential milestone payments of up to €495 million.

Vir expects [additional pivotal results](https://www.biospace.com/drug-development/virs-hepatitis-delta-combo-tamps-down-virus-as-gilead-showdown-looms?ref=bullished.co) in the first quarter of 2027, covering switching from and comparison against Gilead's Hepcludex. It targets an FDA submission for mid-2027.

Learn

- [Item 7.01: Regulation FD disclosure →](https://www.bullished.co/learn/8-k-items-explained/#item-701-regulation-fd-disclosure)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Vir Biotechnology, Inc. (VIR)](https://www.sec.gov/Archives/edgar/data/0001706431/000162828026071908/vir-20261108.htm?ref=bullished.co) — SEC EDGAR
- [Vir hepatitis D drug succeeds in first pivotal study | BioPharma Dive](https://www.biopharmadive.com/news/vir-chronic-hepatitis-d-drug-results-elebsiran-tobevibart/874089/?ref=bullished.co) — biopharmadive.com
- [Vir's hepatitis delta combo tamps down virus as Gilead showdown looms - BioSpace](https://www.biospace.com/drug-development/virs-hepatitis-delta-combo-tamps-down-virus-as-gilead-showdown-looms?ref=bullished.co) — biospace.com
- [Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD's The Liver Meeting® 2026 and Host Investor Conference Call – Company Announcement - FT.com](https://markets.ft.com/data/announce/detail?dockey=600-202611051000BIZWIRE%5FUSPRX%5F%5F%5F%5F20261105%5FBW268667-1&ref=bullished.co) — Financial Times
- [Vir Biotechnology stock jumps 22% after hepatitis delta Phase 3 trial success](https://finance.yahoo.com/markets/stocks/articles/vir-biotechnology-stock-jumps-22-130631799.html?ref=bullished.co) — Yahoo Finance
- [VIR Stock Soars Over 10% Overnight, Eyes Best Year Ever — Hepatitis Win Sparks Buyout Buzz And Bigger Bullish Bets](https://finance.yahoo.com/healthcare/articles/vir-stock-soars-over-10-055942466.html?ref=bullished.co) — Yahoo Finance

### More on Vir Biotechnology

- [State Street Held 4.6% Of Vir Biotechnology Before Its Hepatitis Trial Results](https://www.bullished.co/state-street-held-4-6-of-vir-biotechnology-before-its-hepatitis-trial-results-c0943fcc/)
- [Vir Stock Soars 12% After Hepatitis Delta Trial Meets Its Main Goal](https://www.bullished.co/vir-stock-soars-12-after-hepatitis-delta-trial-meets-its-main-goal-911f982b/)
- [ARCH Funds Sell 347,819 And 448,356 Vir Biotechnology Shares, Retain Stakes](https://www.bullished.co/arch-funds-sell-347-819-and-448-356-vir-biotechnology-shares-retain-stakes-48400650/)

[All Vir Biotechnology (VIR) coverage →](https://www.bullished.co/tag/vir/)